Executive record

Peter Greenleaf

Chairman of the Board at Pelthos Therapeutics Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:peter-greenleaf-auphVersion: public-0As of: 2026-09-29

Not yet claimed14 published Claims5 sources
  • Director

Key Claims

Biography

CEO of Aurinia Pharmaceuticals since April 2019. Previously CEO of Cerecor Pharmaceuticals (2018-2019) and Sucampo Pharmaceuticals (2014-2018). Served as President of MedImmune LLC (AstraZeneca's biologics arm) from 2006-2013.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Director (Chairman of the Board) · Organization not publishedPTHS 10-K executive officers
  2. 2026 to end not publishedExecutive title: President, Chief Executive Officer, Director · Organization not publishedAUPH 10-K executive officers
  3. Dates not publishedExecutive title: President and Chief Executive Officer · Organization not publishedAUPH executive roster source

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Open source

    sec def 14a · Source published: Aug 18, 2026 · Retrieved: Sep 12, 2026

    Supports 1 claim
    • Professional Role: Chairman of the Board at Pelthos Therapeutics Inc. · Claim reviewed: Sep 12, 2026

  2. PTHS 10-K executive officers

    sec filing · Source published: Mar 19, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Pelthos Therapeutics Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director (Chairman of the Board) · Claim reviewed: May 16, 2026
    • Other Company Role: Peter Greenleaf is also linked to Aurinia Pharmaceuticals Inc. as Chief Executive Officer. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. AUPH 10-K executive officers

    sec filing · Source published: Feb 26, 2026 · Retrieved: May 14, 2026

    Supports 2 claims
    • Executive company: Executive at Aurinia Pharmaceuticals Inc. · Claim reviewed: May 14, 2026
    • Executive title: Executive title: President, Chief Executive Officer, Director · Claim reviewed: May 14, 2026

  4. AUPH executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Aurinia Pharmaceuticals Inc. · Claim reviewed: May 14, 2026
    • Executive function: Enterprise Leadership (CEO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 3, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Pelthos Therapeutics Inc. · Claim reviewed: Sep 12, 2026